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In recent years, the advent of genomic 
manipulation of mice has facilitated the 
production of genetically engineered 
mouse models (GEMMs) that realis-
tically recapitulate human cancer (1). 
In particular, the use of site-specific 
recombinases has facilitated the spatio-
temporal mutation of the genome, 
allowing for controlled inactivation of 
tumor suppressors and/or induction 
of endogenous oncogenes (2). Thus, 
activation of the oncogenic alteration 
occurs in adult mice, is restricted to 
limited numbers of selected cell popula-
tions, and is subject to the control of 
endogenous regulatory elements. By 
virtue of these features, the originating 
tumors faithfully mimic the progression 
of human disease. These models offer 
an in vivo scenario amenable to exper-
imental manipulation, providing an 
invaluable tool for the identification of 
the molecular mechanisms that initiate 
and sustain cancer growth. 
GEMMs have also played a key 
role in advancing customized cancer 
treatment by facilitating the validation 
of potential therapeutic targets by 
genetic means. However, although 
conventional genetic validation of 
putative targets based on the ablation 
of endogenous alleles is a robust 
approach, it is also a tedious procedure 
that is far from being a cost- or time-
ef fective alternative. Hence, there 
is an urgent demand for the devel-
opment of a versatile, regulatable, 
and economica l gene target ing 
procedure to allow tumor-specif ic 
target validation in vivo. To this end, 
we have combined in a single lentiviral 
vector all of the functional elements 
required to trigger tumor formation and 
perform preclinical target validation in 
any murine conditional cancer model 
reliant on the Cre-recombinase activity 
with the additional requirement of a 
resident reverse Tet-transactivator 
(rtTA) transgene. Furthermore, we have 
incorporated insulator genetic elements 
to prevent epigenetic silencing of the 
viral sequences, a phenomenon of 
great concern when performing long-
lasting in vivo  experiments.
Materials and Methods
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Despite the pressing need for novel cancer treatments, our improved understanding of tumor biology is 
not being successfully translated into better therapies. Here we present a lentiviral vector that enables 
in vivo validation of cancer therapeutic targets when combined with existing cancer animal models that 
faithfully reproduce the natural history of human disease. Unlike the conventional genetic approaches 
with targeted alleles, the outlined experimental strategy could be used to assess the preclinical 
efficacy of a growing number of putative therapeutic hits in a rapid and cost-effective manner.
Reports
METHOD SUMMARY
We have devised a lentiviral system to be used in combination with any of the widely used conditional oncogenic 
mouse models reliant on the Cre/lox technology. Our approach allows controlled and independent induction 
of both the initiating oncogene as well as regulatable and homogeneous shRNA–mediated knockdown of the 
potential therapeutic target. This is facilitated by the incorporation of functional DNA insulators that prevent 
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Plasmid assembly by Red/ET 
recombination
Plasmid pLB2 (3) was chosen as the 
backbone for assembly of pTOSCA 
and modif ied stepwise by Red/ET 
recombination (4,5). The technology 
relies on in vivo homologous recom-
bination mediated by the Rac-phage 
recE and recT genes or the phage 
lambda reda and redb genes (6) and 
requires, in contrast to other technol-
ogies, no specif ic recombination 
sites. It is therefore possible to insert 
functional elements at virtually every 
position in a large plasmid. Typically, 
Red/ET recombination occurs between 
a linear and a circular reaction partner 
using homology arms of approximately 
50 bp in length (7), which are conve-
niently attached to the linear reaction 
partner by polymerase chain reaction 
(PCR).
For the majority of the steps, Red/
ET recombination was per formed 
according to a standard protocol of 
Gene Bridges GmbH (Heidelberg, 
Germany). Brief ly, PCR fragments 
were amplified from different plasmids 
carrying the corresponding functional 
element of choice and combined with a 
selectable marker gene by another PCR 
reaction. The obtained amplicons were 
gel purified. Bacterial cells harboring 
pRed/ET and the circular plasmid in 
which the functional element should be 
integrated were cultured aerobically in 
1.4 mL of Luria-Broth (LB) medium at a 
temperature of 30°C. At an A600 of 0.3, 
expression of red genes was induced by 
the addition of 50 ml 10% (w/v) arabinose 
and the temperature was increased to 
37°C to ensure maximal expression and 
activity of the recombination proteins 
and prohibit replication of pRed/ET. 
After 45 min, cells were sedimented, 
washed twice with ice-cold 10% (v/v) 
glycerol, and electroporated with 100 
ng of the corresponding PCR product. 
Samples from which L-arabinose was 
omitted were used as negative controls. 
Figure 1. Schematic representation of the lentiviral plasmid pTOSCA (tetracycline operated silenc-
ing and Cre-ERT2 activation) constituents. A doxycycline-responsive promoter (TRE, tet-responsive 
element) controls the expression of a fluorescent spacer (EGFP) together with the shRNAmir30 
that is inserted by replacing the kanamycin resistance marker (KanR) with the indicated restric-
tion enzymes. The zeocin resistance gene (ZeoR) is included as a second selectable marker to 
diminish backbone recombination and ensure plasmid stabilization after the replacement of KanR 
by the shRNA. The constitutive EF1A promoter drives expression of the tamoxifen-inducible Cre 
recombinase (Cre-ERT2) together with the puromycin resistance marker (PuroR) as a bicistronic 
unit by means of the T2A peptide. Upon long terminal repeat (LTR)-mediated integration into the 
host genome, the plasmid backbone is flanked by the genetic elements scaffold attachment re-
gion (SAR) and antirepressor (anti-REP) to minimize epigenetic silencing. The region in between 
LTR sequences contains elements for plasmid amplification in bacteria (replication origin and 
ampicillin resistance). WPRE: woodchuck hepatitis virus posttranscriptional regulatory element.
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5’ LTR (2264-2938)
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After electroporation, cultures were 
plated on LB agar containing appro-
priate antibiotics for the selection 
of the modif ied plasmid. A combi-
nation of Red/ET recombination and 
unique restriction site elimination was 
used when necessary (8). Functional 
elements were obtained from the 
following plasmids: TRE-EGFP-miRNA 
cassette from plasmid pTGM (Plasmid 
#32716, Addgene, Cambridge, MA); 
CreERT2 from Gene Bridges (product 
#A013); FRT-PGK-gb2-neo-FRT from 
Gene Bridges (product #A002); and 
T2A-puro-zeo, a combined building 
block from plasmid pCAGGS-FLPe 
(Gene Bridges product #A201) and a 
synthesized fragment.
shRNA sequence  prediction 
and subcloning
To identify optimal small hairpin RNA 
(shRNA) triggers, first we defined the 
target sequence as the set of mRNA 
sequences common to al l target 
isoforms as determined by the Refseq 
IDs of the intended target. All possible 
21-nucleotide small interfering RNA 
(siRNA) sequences were then generated 
and scored according to the method 
of Vert and colleagues (9), and the top 
5% were used for the steps that follow. 
Next, we defined a linear predictor score 
(LPS) for each sequence by combining 
features, including (i ) relative content 
of each nucleotide, (ii ) any nucleotide 
repeat or combination of repeats, and 
(iii ) 5´-to-3´ sequence asymmetry. The 
LPS distribution of efficient shRNAs 
was based on experimentally validated 
shRNAs and shRNAs scoring in mir30-
based RNAi screens (10–12). Control 
sequences included all nonscoring 
shRNAs targeting the same genes 
for which the experimentally validated 
shRNAs described were available. Only 
features enriched at least 2-fold in the 
efficient shRNAs set compared with the 
nonscoring shRNAs set were included 
in the LPS. A probability for efficient 
shRNA was then calculated based on 
the LPS distribution of efficient shRNAs 
according to Bayes’ rules. The resulting 
shRNAs (P > 0.8) were embedded in 
the mir30 backbone as previously 
described (13) with the corresponding 
modifications to incorporate the recog-
nition sequences for Sbf1 and Asc1 
restriction enzymes at the 5´ and 3´ 
ends, respectively. The sequence of the 




CATCTC CATG C CACTG C CTACT-
GCCTCGGA-3´.
In vitro validation
Lentiviral particles were produced in 
293T packaging cells, concentrated 
by ultracentrifugation, and titrated 
as previously described (14). Mouse 
embryonic fibroblasts (MEFs) consti-
tutively expressing the rtTA transac-
tivator were infected, selected with 2 
mg/mL puromycin for 72 h, and grown 
with or without 1µg/ml doxycycline for 
an additional 72 h. Cells were harvested 
and processed for Western blotting 
procedures as previously described (15) 
or analyzed by FACS to monitor GFP 
induction as a surrogate marker of micro 
RNA (miRNA) expression.
In vivo validation
K-RasLSLG12Vgeo and Rosa26LSLrtTA mice 
have been previously described (16,17). 
Mice were infected intra-tracheally 
with 104 viral particles as previously 
described (15). Cre-mediated induction 
of the K-RasG12V oncogene was induced 
by intraperitoneal administration of 1 
mg of 4-hydroxytamoxifen (4OHT) as 
described (16). When indicated, mice 
were fed ad libitum a doxycycline 
containing diet (D12100401, Research 
Diets, New Brunswick, NJ) for the entire 
duration of the experiment. Histopath-
ologic analysis, immunostaining, and 
quantification of tumor burden were 
per formed on lung serial sections 
as described (15). All strains were 
genotyped by Transnetyx (Cordova, TN).
Results and discussion
Here we set out to optimize a rapid and 
flexible method for the in vivo validation 
of putative cancer therapeutic targets. 
To this end, we devised a lentiviral-based 
approach that allows controlled and 
independent induction of both the initi-
ating cancer event and the knockdown 
of potential therapeutic targets. We have 
selected the site-specific recombinase 
Cre/lox system as a tumor-promoting 
tool because it has been widely used 
to trigger cancer initiation in GEMMs 
by ablation of tumor suppressors; 
activation of endogenous oncogenes; 
or induction of chromosomal translo-
cations, deletions, or inversions (2). In 
our system, tumor initiation and target 
silencing are both achieved by means 
of a lentiviral construct developed as a 
recipient vector for any miR30-based 
shRNA together with an expression 
cassette containing the Cre recom-
binase (Figure 1). We decided to use 
a tamoxifen-inducible Cre version 
(Cre-ERT2) because i t has been 
shown to lack toxic side effects at the 
cellular level compared with consti-
tutive expression of the conventional 
Cre recombinase (18). As the second 
constituent of the lentiviral module, we 
used a doxycycline-inducible miR30-
based shRNA expression cassette 
Figure 2. Evaluation of DNA-insulating properties in vivo. 
CD4+ T cells expressing GFP were generated by 
lentiviral infection of bone marrow and reconsti-
tution into irradiated hosts. T cells were analyzed 
by FACS eight weeks after reconstitution for GFP 
expression in the absence and presence of DNA 
insulating elements as indicated. Mean fluores-
cence intensity (MFI) is shown ± standard devia-
tion. CMV: cytomegalovirus. 
Lentiviral backbone MFI ± SD 
CMV-GFP 18 ± 10 
CMV-GFP + DNA 




CMV-GFP + DNA insulators 
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linked to a fluorescent reporter that 
has been ef fectively harnessed to 
induce target knockdown in vivo 
(19). Finally, epigenetic silencing of 
viral constructs is a serious concern 
when the in vivo approach relies on 
consistent and long-term expression 
of a particular transcript. Silencing 
is of particular concern in conditions 
in which specific genetic manipula-
tions may confer a selective disad-
vantage. To counteract this problem, 
we flanked our expression cassette 
with two DNA-insulating elements that 
have been shown to confer position-
independent and long-term transgene 
expression in vivo (3, 20). We decided 
to incorporate two DNA insulators 
that, when inserted into a lentiviral 
vector, increased the penetrance and 
expression of a GFP transgene from 
20% (no insulator control) to approxi-
mately 70% after 5 generations (3). To 
further assess the advantage conferred 
by these DNA-insulating elements, we 
purified Lin- bone marrow stem cells 
and infected them with GFP-expressing 
lentiviral particles followed by injection 
into irradiated syngeneic recipient mice. 
Eight weeks after reconstitution, spleen 
cells were analyzed for GFP expression 
by FACS. Remarkably, the presence of 
both DNA insulators resulted in a signif-
icant increase of the mean fluorescence 
intensity of splenic CD4+ T cells (Figure 
2). It has been recently reported that 
long-term transgene expression can 
be achieved upon lentiviral delivery 
in vivo (21, 22). However, because of 
Figure 3. Outline of the target validation procedure. Upon subcloning of the shRNA candidate sequences, the plasmid is used to generate lentiviral particles 
following standard methodology. Infection of rtTA-expressing cells is used for the evaluation of the most effective sequences; expression of a fluorescent spacer 
(EGFP) is used as a surrogate marker to confirm infection efficiency. The selected lentiviral particles are used to infect mice carrying an rtTA knock-in together 
with a Cre/lox-inducible cancer-initiating genetic element. This could be a silent knock-in oncogenic mutation controlled by a floxed transcriptional stop cassette 
(LSL) or a tumor suppressor flanked by loxP sites. The choice of infection route may vary depending on the tumor type. The doxycycline (doxy) regimen can be 
adjusted to assess the role of the putative target during tumor initiation (left) as well as to evaluate its therapeutic efficacy (right). 4OHT: 4-hydroxytamoxifen.
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the random integration of the lenti-
viral backbone, local transcription 
control can have a mixed effect on 
expression of the integrated construct, 
resulting in a high degree of variation. 
The insulator elements help to maintain 
long-term expression and diminish local 
variability (Figure 2). For these reasons, 
the presence of the insulator sequences 
may be advantageous in applications 
subject to negative selection as in the 
case of validation of putative cancer 
therapeutic targets.
We nex t decided to test the 
efficacy of the lentiviral approach in an 
aggressive tumor model (the routine 
experimental layout is shown in Figure 
3). To this end, we focused on the K-Ras 
oncogene that is present in over 30% 
of all human non–small cell lung cancer 
(NSCLC). Furthermore, unlike other 
subtypes of NSCLC driven by alternative 
oncogenes such as mutant epidermal 
growth factor receptor or EML4-ALK, 
currently there is no targeted therapy 
to treat K-Ras mutant patients. Thus, 
we selected a K-Ras–driven cancer 
model as a proof of concept to evaluate 
our target validation set-up in vivo. We 
have used an inducible K-RasG12V strain 
engineered as a knock-in mutation 
within the endogenous locus that is 
maintained silent by a preceding floxed 
transcription stop cassette (Lox-Stop-
Lox or LSL). Activation of the endog-
enous K-Ras mutant allele is induced 
upon Cre-mediated excision of the LSL 
cassette, resulting in the development 
of NSCLC (16).
Following a conventional genetic 
approach, C-Raf has been recently 
shown to be an essential mediator of 
oncogenic K-Ras in NSCLC (15,23). 
Therefore, we decided to use the 
C-Raf kinase as a contingent thera-
peutic target to evaluate the lentiviral-
mediated methodology. Optimal shRNA 
sequences targeting the C-Raf kinase 
were generated by a classifier based on 
balanced voting between four machine-
learning tools, which were trained on 
experimentally validated shRNAs (24) 
and shRNAs scoring in several mir30-
based RNAi screen (C.S., manuscript 
in preparation). The lentiviral construct 
carries puromycin N-acetyl-transferase 
as a selectable marker downstream of 
the Cre-ERT2 and linked by the 2A 
peptide that facilitates the synthesis 
of multiple gene products from single 
transcr ipts. This al lowed in v itro 
selection of the most effective shRNA 
sequences upon infection of cells 
Figure 4. Lentiviral-mediated validation of C-Raf kinase as an essential mediator in K-RasG12V-driven non–small cell lung carcinoma. (A) Infection of rtTA-ex-
pressing mouse embryonic fibroblasts (MEFs) with lentiviral particles carrying shRNA sequences against C-Raf. Induction of expression of a fluorescent spacer 
(EGFP) as well as C-Raf knockdown efficacy were assessed by FACS and Western blotting after three days in the presence of doxycycline (doxy; upper West-
ern blot panels). Performance of the system at low multiplicity of infection (MOI) was also assessed (lower Western blot panels). GAPDH is shown as a loading 
control. (B) Representative images of hematoxylin and eosin–stained lung sections from K-RasLSLG12Vgeo, Rosa26LSLrtTA mice. All mice received a single 1 mg dose 
of 4-hydroxytamoxifen (4OHT) and after 3 days were maintained on a doxycycline containing diet (n = 7) or control diet (n = 4) for 6 months. (C) Quantifica-
tion of the number of lesions six months after the lentiviral infection in controls and doxycycline-treated cohort. Data are shown as mean ± standard deviation.
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expressing rtTA (Figure 4A). Importantly, 
efficient knockdown of the target was 
achieved at a multiplicity of infection 
(MOI) of 1, demonstrating single copy 
efficacy, thus reinforcing the notion 
that this is a feasible approach in vivo 
(Figure 4A). K-RasLSLG12Vgeo, Rosa26LSLrtTA 
mice carrying the endogenous K-RasG12V 
oncogene as well as an rtTA targeted 
to the Rosa26 locus (17) were infected 
intra-tracheally with the selected lenti-
viral particles. We have used 104 viral 
par ticles /mouse because this has 
been previously shown to efficiently 
induce tumor formation in a similar 
Cre-dependent model (25). After three 
days, all animals were subjected 4OHT 
injections to activate the Cre-ERT2 
recombinase and induce expression of 
both the endogenous K-Ras oncogene 
as well as the rtTA. At this point, a cohort 
of mice was fed a doxycycline-containing 
diet to induce C-Raf knockdown upon 
expression of the specific shRNA. The 
diet was maintained for a period of 
6 months to assess the stability and 
long-term in vivo performance of the 
system. As expected, histologic charac-
terization of the lungs from the control 
(doxycycline free, n = 4) cohort identified 
tumor lesions classif ied as adeno-
carcinomas in all examined animals. 
Remarkably, all inspected mice from 
the doxycycline diet cohort (n = 7) were 
found to be tumor free (Figure 4B). An 
unrelated shRNA did not interfere with 
tumor development (data not shown). 
These tumors were used to assess the 
homogeneous expression of the shRNA 
by means of the GFP reporter (Supple-
mentary Figure S1). In sum, these 
results demonstrate that our shRNA-
mediated lentiviral strategy is a feasible 
approach for long-term target validation 
purposes in vivo.
Over the past two decades, our 
improved understanding of the biology 
of cancer has resulted in the identifi-
cation of molecular and cellular traits 
that are exclusive to tumor cells. As a 
consequence, drug development has 
shifted toward agents that target these 
specif ic molecular alterations. The 
resulting targeted cancer therapies 
offer tumor-specific selectivity and as 
a consequence may be more effective 
than conventional cytotoxic regimens 
and substantially less harmful to normal 
cells. Such an approach is particularly 
relevant for tumor types that remain 
elusive targets for conventional therapy. 
Among those, cancers carrying the 
K-Ras oncogene are a paradigmatic 
example. K-Ras–activating mutations 
result in aggressive tumors, generally 
correlate with a poor prognosis, and are 
associated with mediocre response to 
many existing treatments (26). Recent 
therapeutic efforts have used unbiased 
functional genomics and synthetic lethal 
screens in search of K-Ras–specific 
pharmacologically tractable targets 
(27). Actually, comprehensive methods 
integrating various high-throughput 
approaches have been implemented 
(28,29), and the concerted outcome 
of all these ef forts has provided a 
significant number of putative thera-
peutic targets that may eventually join 
the pipeline of candidates in need of 
pharmacologic development. Ideally, 
these targets should formerly undergo 
rigorous functional validation in vivo. 
This is an important issue because 
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many candidate therapeutic targets 
have ultimately failed to induce stable 
tumor remission when translated to 
clinical trials (30). We believe that the 
lentiviral approach described here will 
facilitate a rapid and cost-effective in 
vivo validation of putative therapeutic 
targets in a number of aggressive tumor 
types. Other delivery routes could be 
used for the induction of tumors in 
tissues other than lung (21).
In addition to the target validation 
method outlined earlier, several other 
applications could be implemented 
based on minor modifications of the 
existing viral backbone subject to lenti-
viral packaging limits. For instance, 
expression of additional cDNAs could 
be achieved by converting the bicis-
tronic transcript into a multicistronic 
unit by means of further self-processing 
2A peptides. This could be used for 
the expression and functional evalu-
ation of presumed co-driver mutations. 
Furthermore, our system is readily 
compatible with a number of new 
mir-RNA based improved structures 
(31). Finally, the emergence of resis-
tance is one of the major hurdles faced 
by those targeted therapies currently 
undergoing clinical trials (30). Several 
applications could be used to inves-
tigate and validate mechanisms of 
drug resistance, both intrinsic and 
acquired. The lentiviral approach could 
be combined with already existing 
pharmacologic treatments to validate 
candidate mediators of intrinsic resis-
tance. In this setting, the inducible 
shRNA knockdown could be used to 
reassess therapeutic ef f icacy upon 
inactivation of putative drug ef f lux 
transporters, drug modifiers, or anti-
apoptotic/pro-survival factors. Impor-
tantly, the mir30 system enables two 
shRNAs to be linked together in cis, 
allowing co-knockdown of two targets 
to assess combination therapies 
(20,32). In addition, tumors become 
treatment refractory by acquired resis-
tance because of secondary mutations. 
Anticipating the nature of these resis-
tance dr ivers could a l low in i t ia l 
co-targeting of the relevant pathways 
to enhance therapeutic efficacy. To this 
end, the lentiviral system can be used 
to anticipate mechanisms of drug resis-
tance in vivo by performing sequential 
on–off doxycycline intervals resulting in 
intermittent target inhibition. This is an 
advantage compared with permanent 
gene editing procedures such as CRISP/
Cas technology (33). This alternating 
regimen mimics clinical practice and 
has been previously shown to facilitate 
the selection of mutant drug-resistant 
tumor subclones (34). This protocol 
may help the expansion of clones with 
mutations affecting other proteins that 
deregulate the driver oncogene or alter-
native signaling pathways (or both). 
Both can be subsequently identified 
by deep sequencing approaches.
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